Bionano Genomics posts 4% revenue growth in Q1 2026, driven by increased consumables sales and expanding OGM adoption.

Bionano Genomics reported a 4% revenue increase to $6.7 million in Q1 2026, with consumables revenue up 20% and strong growth in nanochannel array flow cell sales. The company highlighted expanding clinical adoption of its optical genome mapping (OGM) technology, supported by new CPT codes and increased reimbursement rates. Bionano also noted growing scientific validation through publications and expects Q2 revenue between $7.5-$7.8 million and full-year 2026 revenue of $30-$33 million. The company is nearing retirement of secured convertible debt, aiming to strengthen its financial position for future growth.